Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CFT1946 · 1 trial · 5 indications
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 2 only according to RECIST v1.1 criteria
Phase 2
Phase 2
| Arm | Type | Description |
|---|---|---|
| Phase 1: Arm A: CFT1946 | EXPERIMENTAL | Approximately 40 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma, ATC) |
| Phase 1: Arm B: CFT1946 + trametinib | EXPERIMENTAL | Approximately 28 subjects with V600 Solid Tumors (non-CNS) (post BRAF inhibitor for NSCLC, CRC, melanoma) |
| Phase 2: Arm A1: CFT1946 | EXPERIMENTAL | Approximately 30 subjects with V600 melanoma or NSCLC (post BRAF inhibitor) |
| Phase 2: Arm B1: CFT1946 + trametinib | EXPERIMENTAL | Approximately 20 subjects with V600 melanoma or NSCLC (post BRAF Inhibitor) |
| Phase 1: Arm C: CFT1946 + cetuximab | EXPERIMENTAL | Approximately 30 subjects with CRC (post BRAF inhibitor) |
| Phase 2: Arm C1: CFT1946 + cetuximab | EXPERIMENTAL | Approximately 40 subjects with CRC (post BRAF inhibitor) |
| Name | Type | Description |
|---|---|---|
| CFT1946 | DRUG | Specified oral dose on specified day |
| Trametinib | DRUG | Specified oral dose on specified day |
| Cetuximab | DRUG | Specified intravenous dose on specified day |
Inclusion Criteria: 1. Subject (or legally authorized representative, where applicable) is willing and able to provide signed informed consent and can follow protocol requirements 2. Subject is ≥18 years of age at time of informed consent 3. Eastern Cooperative Oncology Group performance status of ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CFT1946 is an investigational small molecule developed by C4 Therapeutics, Inc. (ticker CCCC) for the treatment of BRAF V600 mutant solid tumors. It is being studied as both a monotherapy and in combination therapy in adult patients with cancers including melanoma, NSCLC, CRC, and ATC.
CFT1946 is being developed for BRAF V600 mutant solid tumors. The Phase 1 study enrolled patients with melanoma, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and anaplastic thyroid cancer (ATC). It is investigational and has not been approved for any indication.
CFT1946 targets BRAF V600, a mutant form of the BRAF protein. It is a small molecule designed to act against tumors carrying this specific mutation. The Phase 1 trial was biomarker-selected, enrolling only patients whose tumors harbor the BRAF V600 mutation.
CFT1946 is being developed by C4 Therapeutics, Inc., which trades on the Nasdaq under the ticker CCCC. The company is the sponsor of the clinical program evaluating CFT1946 in BRAF V600 mutant solid tumors.
CFT1946 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The Phase 1 trial has been completed, and no active trials are currently listed for this asset.
CFT1946 was evaluated in one Phase 1 trial, NCT05668585, titled a study to characterize the safety, tolerability, and preliminary efficacy of CFT1946 as monotherapy and combination therapy in subjects with BRAF V600 mutant solid tumors. The trial enrolled 89 patients across the United States, France, Germany, Spain, and the United Kingdom, and is completed.